Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ropinirole IR · 1 trial · 2 indications
AE is an unfavorable change in the health of a participant, including abnormal laboratory findings, that happens during a clinical study or within a certain time period after the study has ended. This change may or may not be caused by the intervention being studied. In each of the 6 cohorts, there were 2 conversions, one of which was IR to CR-RLS and the other one IR to IR. Two populations were defined: the first conversion population and the second conversion population. The first conversion population consisted of all participants receiving at least one dose of randomized drug during the pre-conversion 1 period and during the post-conversion 1 period. The second conversion population consisted of all participants receiving at least one dose of randomized drug during the pre-conversion 2 period and during the post-conversion 2 period.
| Arm | Type | Description |
|---|---|---|
| Ropinirole cohort A1: 1 mg IR/2 mg CR-RLS/1 mg IR/1 mg IR | EXPERIMENTAL | Participants received Placebo in the evening and Ropinirole 1 mg IR at bedtime on Week 1. At the end of Week 1, participants were switched to receive Ropinirole 2 mg controlled release for Restless Legs Syndrome (CR-RLS) in the evening and placebo at bedtime till the end of Week 2. At the end of Week 2, participants were converted back to receive placebo in the evening and Ropinirole 1 mg IR at bedtime and continued to receive the same till the end of Week 4. |
| Ropinirole cohort A2: 1 mg IR/1 mg IR/1 mg IR/2 mg CR-RLS | EXPERIMENTAL | Participants received Placebo in the evening and Ropinirole 1 mg IR at bedtime on Week 1 and continued to receive the same till the end of Week 3. At the end of Week 3, participants were switched to receive Ropinirole 2 mg CR-RLS in the evening and placebo at bedtime till the end of Week 4. |
| Ropinirole cohort B1: 2 mg IR/3 mg CR-RLS/2 mg IR/2 mg IR | EXPERIMENTAL | Participants received Placebo in the evening and Ropinirole 2 mg IR at bedtime on Week 1. At the end of Week 1, participants were switched to receive Ropinirole 3 mg CR-RLS in the evening and placebo at bedtime till the end of Week 2. At the end of Week 2, participants were converted back to receive placebo in the evening and Ropinirole 2 mg IR at bedtime and continued to receive the same till the end of Week 4. |
| Ropinirole cohort B2: 2 mg IR/2 mg IR/2 mg IR/3 mg CR-RLS | EXPERIMENTAL | Participants received Placebo in the evening and Ropinirole 2 mg IR at bedtime on Week 1 and continued to receive the same till the end of Week 3. At the end of Week 3, participants were switched to receive Ropinirole 3 mg CR-RLS in the evening and placebo at bedtime till the end of Week 4. |
| Ropinirole cohort C1: 4 mg IR/6 mg CR-RLS/4 mg IR/4 mg IR | EXPERIMENTAL | Participants received Placebo in the evening and Ropinirole 4 mg IR at bedtime on Week 1. At the end of Week 1, participants were switched to receive Ropinirole 6 mg CR-RLS in the evening and placebo at bedtime till the end of Week 2. At the end of Week 2, participants were converted back to receive placebo in the evening and Ropinirole 4 mg IR at bedtime and continued to receive the same till the end of Week 4. |
| Ropinirole cohort C2: 4 mg IR/4 mg IR/4 mg IR/6 mg CR-RLS | EXPERIMENTAL | Participants received Placebo in the evening and Ropinirole 4 mg IR at bedtime on Week 1 and continued to receive the same till the end of Week 3. At the end of Week 3, participants were switched to receive Ropinirole 6 mg CR-RLS in the evening and placebo at bedtime till the end of Week 4. |
| Name | Type | Description |
|---|---|---|
| Ropinirole IR 1 mg | DRUG | Ropinirole IR (SKF-101468) will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 1.0mg of active drug substance. |
| Ropinirole IR 2 mg | DRUG | Ropinirole IR (SKF-101468) will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 2.0mg of active drug substance. |
| Ropinirole IR 1 mg Placebo | DRUG | Ropinirole IR (SKF-101468) placebo will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing matching placebo tablets of 1 mg. |
| Ropinirole IR 2 mg Placebo | DRUG | Ropinirole IR (SKF-101468) placebo will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing matching placebo tablets of 2 mg. |
| Ropinirole CR 2 mg | DRUG | Ropinirole CR Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 2mg of the active drug substance. |
| Ropinirole CR 3 mg | DRUG | Ropinirole CR Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 3mg of the active drug substance. |
| Ropinirole CR 2 mg Placebo | DRUG | Ropinirole CR placebo Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing matching placebo tablets of 2 mg. |
| Ropinirole CR 3 mg Placebo | DRUG | Ropinirole CR placebo Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing matching placebo tablets of 3 mg. |
Inclusion Criteria: * Diagnosis of RLS using IRLS Study Group (IRLSSG) diagnostic criteria. * Subjects currently being treated for RLS with a stable dose (for at least 2 weeks) of ropinirole IR given once daily. * Subjects with RLS symptoms during both the evening and night or night time only. * Su...
Ropinirole IR is used to treat Restless Legs Syndrome, a neurological condition that causes an uncontrollable urge to move the legs. It is an immediate-release small molecule formulation developed by GSK plc. The drug is studied in adults 18 years and older.
Ropinirole IR targets the dopamine receptors DRD2, DRD3, and DRD4, where it acts as an agonist. By stimulating these receptors, it is designed to address the symptoms of Restless Legs Syndrome. This receptor activity is the basis of its use in Neurology.
Ropinirole IR is developed by GSK plc, which trades under the ticker GSK. The company is responsible for the clinical development of the immediate-release formulation for Restless Legs Syndrome.
Ropinirole IR is in Phase 3 clinical development for Restless Legs Syndrome. It is an investigational small molecule and is not stated to be approved. The Phase 3 trial has been completed, and no active trials are currently listed.
Ropinirole IR has been studied in one Phase 3 trial, NCT00256854, titled Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS. The trial enrolled 135 participants in the United States, was randomized and controlled, and has been completed.